10x genomics, inc.TXG.US Overview
TXG Overall Performance
TXG AI Analysis & Strategy
Browsing restrictions can be lifted for a fee.
TXG Current Performance
-0.45%
10x genomics, inc.
-1.93%
Avg of Sector
-0.59%
S&P500
TXG Key Information
TXG Financial Forecast
Browsing restrictions can be lifted for a fee.
| Quarterly | EPS Forecast | QoQ | Max | Min |
|---|---|---|---|---|
| 2025Q1 | ||||
| 2025Q2 | ||||
| 2025Q3 | ||||
| 2025Q4 | ||||
| 2026Q1 |
TXG Earnings Table
Unit : USD
| QTR | Non-GAAP EPS | EPS YoY | EPS Surprise % | Sales | Sales YoY | Sales Surprise % | NPM |
|---|---|---|---|---|---|---|---|
| Current | |||||||
| 2024Q4 | |||||||
| 2024Q3 | |||||||
| 2024Q2 | |||||||
| 2024Q1 |
TXG Profile
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the activity of immune cells and their targets; single cell Assay for Transposase Accessible Chromati (ATAC) for measuring epigenetics comprising the physical organization of DNA; and single cell multiome ATAC + gene expression for measuring the genetic activity and epigenetic programming in the same cells across tens of thousands of cells in a single experiment. The company also provides visium spatial gene expression solution for measuring spatial gene expression patterns across a single tissue sample or gene expression and protein co-detection when combined with immunofluorescence. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
Price of TXG
TXG FAQ
When is TXG's latest earnings report released?
The most recent financial report for 10x genomics, inc. (TXG) covers the period of 2025Q2 and was published on 2025/06/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating TXG's short-term business performance and financial health. For the latest updates on TXG's earnings releases, visit this page regularly.
What is the operating profit of TXG?
According to the latest financial report, 10x genomics, inc. (TXG) reported an Operating Profit of 30.13M with an Operating Margin of 17.42% this period, representing a growth of 172.18% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.
How is TXG's revenue growth?
In the latest financial report, 10x genomics, inc. (TXG) announced revenue of 172.91M, with a Year-Over-Year growth rate of 12.93%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.
How much debt does TXG have?
As of the end of the reporting period, 10x genomics, inc. (TXG) had total debt of 86.74M, with a debt ratio of 0.09. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.
How much cash does TXG have?
At the end of the period, 10x genomics, inc. (TXG) held Total Cash and Cash Equivalents of 397.71M, accounting for 0.41 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
Does TXG go with three margins increasing?
In the latest report, 10x genomics, inc. (TXG) achieved the “three margins increasing” benchmark, with a gross margin of 72.3%%, operating margin of 17.42%%, and net margin of 20%%. This demonstrates improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess TXG's profit trajectory and future growth potential.
Is TXG's EPS continuing to grow?
According to the past four quarterly reports, 10x genomics, inc. (TXG)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at 0.28. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.
What is the FCF of TXG?
10x genomics, inc. (TXG)'s Free Cash Flow (FCF) for the period is 16.13M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 249.29% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.
What are the PEG ratio and PE ratio of TXG?
The latest valuation data shows 10x genomics, inc. (TXG) has a Price-To-Earnings (PE) ratio of -18.09 and a Price/Earnings-To-Growth (PEG) ratio of -0.05. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.